Abstract
Many new targeted anticancer drugs have been developed. In order for these drugs to be effective, the tumor target has to be present during treatment. Currently there are only a few biomarkers available to help the physician select the appropriate targeted drug for the patient and often tumor tissue is required for biomarker assays. Immunoscintigraphy might be able to improve diagnostic imaging, to guide antibody based therapy and to support early antibody development. Many different radiopharmaceuticals have been developed and used to visualize all kind of different targets especially in oncology. Intact radiolabeled antibodies generally show high tumor uptake but low tumor-to-blood ratios, particularly at early time points. Radiolabeled antibody fragments and proteins show widely differing values for tumor uptake and tumor- to-blood contrast. One of the promising targets for visualization might be HER2/neu. HER2/neu scans may prove useful for tumor staging, guiding of targeted therapy and measuring target occupancy in early drug development. Immunoscintigraphic clinical studies performed with intact antibodies indicate that HER2/neu imaging is feasible. Additional research will be performed to prove its value and make this technique applicable on a larger scale. The aim of this review is to describe the types of radiopharmaceuticals that are available, and the potential role of immunoscintigraphy in improving diagnostic imaging, guiding monoclonal antibody (mAb)-based therapy and supporting the development of mAb-based drugs using the HER2/neu target as an example.
Keywords: Radioimmunoscintigraphy, HER2/neu, diagnostic imaging, targeted therapy, antibodies
Current Pharmaceutical Design
Title: Immunoscintigraphy as Potential Tool in the Clinical Evaluation of HER2/neu Targeted Therapy
Volume: 14 Issue: 31
Author(s): Eli C.F. Dijkers, Elisabeth G.E. de Vries, Jos G.W. Kosterink, Adrienne H. Brouwers and Marjolijn N. Lub-de Hooge
Affiliation:
Keywords: Radioimmunoscintigraphy, HER2/neu, diagnostic imaging, targeted therapy, antibodies
Abstract: Many new targeted anticancer drugs have been developed. In order for these drugs to be effective, the tumor target has to be present during treatment. Currently there are only a few biomarkers available to help the physician select the appropriate targeted drug for the patient and often tumor tissue is required for biomarker assays. Immunoscintigraphy might be able to improve diagnostic imaging, to guide antibody based therapy and to support early antibody development. Many different radiopharmaceuticals have been developed and used to visualize all kind of different targets especially in oncology. Intact radiolabeled antibodies generally show high tumor uptake but low tumor-to-blood ratios, particularly at early time points. Radiolabeled antibody fragments and proteins show widely differing values for tumor uptake and tumor- to-blood contrast. One of the promising targets for visualization might be HER2/neu. HER2/neu scans may prove useful for tumor staging, guiding of targeted therapy and measuring target occupancy in early drug development. Immunoscintigraphic clinical studies performed with intact antibodies indicate that HER2/neu imaging is feasible. Additional research will be performed to prove its value and make this technique applicable on a larger scale. The aim of this review is to describe the types of radiopharmaceuticals that are available, and the potential role of immunoscintigraphy in improving diagnostic imaging, guiding monoclonal antibody (mAb)-based therapy and supporting the development of mAb-based drugs using the HER2/neu target as an example.
Export Options
About this article
Cite this article as:
Dijkers C.F. Eli, de Vries G.E. Elisabeth, Kosterink G.W. Jos, Brouwers H. Adrienne and Lub-de Hooge N. Marjolijn, Immunoscintigraphy as Potential Tool in the Clinical Evaluation of HER2/neu Targeted Therapy, Current Pharmaceutical Design 2008; 14 (31) . https://dx.doi.org/10.2174/138161208786549425
DOI https://dx.doi.org/10.2174/138161208786549425 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
RNAi Screening for the Discovery of Novel Modulators of Human Disease
Current Pharmaceutical Biotechnology Poly-L-arginine: Enhancing Cytotoxicity and Cellular Uptake of Doxorubicin and Necrotic Cell Death
Anti-Cancer Agents in Medicinal Chemistry 4t-CHQ a Spiro-Quinazolinone Benzenesulfonamide Derivative Induces G0/G1 Cell Cycle arrest and Triggers Apoptosis Through Down-Regulation of Survivin and Bcl2 in the Leukemia Stem-Like KG1-a Cells
Anti-Cancer Agents in Medicinal Chemistry Editorial: Exploring Lipid-related Treatment Options for the Treatment of NASH
Current Vascular Pharmacology Drug Repurposing in Chemical Genomics: Can We Learn from the Past to Improve the Future?
Current Topics in Medicinal Chemistry Autoimmune Hepatitis
Current Pediatric Reviews Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design EDITORIAL (Hot Topic: Cancer Chemoresistance and DNA Repair)
Current Medicinal Chemistry Approaches to Targeting Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Prevention and Management of Hypertension Without Drugs
Current Hypertension Reviews AP-1 a Target for Cancer Prevention
Current Cancer Drug Targets EGFR(S) Inhibitors in the Treatment of Gastro-Intestinal Cancers: Whats New?
Current Drug Targets Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Psoriasis and Vascular Risk : An Update
Current Pharmaceutical Design Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect
Current Drug Therapy Molecular Targets of the Nitrogen Containing Bisphosphonates: The Molecular Pharmacology of Prenyl Synthase Inhibition
Current Pharmaceutical Design Comparative Analysis of Spouse’s Burden and Quality of Life in Major Depressive Disorder and Bipolar I Disorder
Current Psychiatry Research and Reviews Promises and Challenges of Adult Stem Cells in Cancer Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Genetically Modified Cellular Vaccines for Therapy of Human Papilloma Virus Type 16 (HPV 16)-Associated Tumours
Current Cancer Drug Targets Targeting Cell Cycle Kinases for Cancer Therapy
Current Medicinal Chemistry